Market Overview

Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines

Share:
Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines

Bristol-Myers Squibb Co (NYSE: BMY)'s quest to expand its oncology franchise through its proposed acquisition of Celgene Corporation (NASDAQ: CELG) may not be a wise move, according to Argus.

The Analyst

David Toung downgraded Bristol-Myers Squibb from Buy to Hold, citing significant risks arising from the Celgene merger.

The Thesis

Bristol-Myers Squibb's growth prospects following the planned acquisition of Celgene are a cause of concern, Toung said in a Friday downgrade note. (See his track record here.) 

The primary concern is the loss of exclusivity and patent cliff issue for Celgene's Revlimid, the analyst said. 

Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.

Toung said he's not confident about Celgene's pipeline delivering sufficient revenue to offset the eventual decline in Revlimid revenues when it loses its exclusivity in 2026.

Additionally, Bristol-Myers Squibb's Opdivo could come under pressure from Merck & Co., Inc. (NYSE: MRK)'s Keytruda, as the latter establishes its supremacy in the first-line treatment of non-small cell lung cancer, the analyst said.

Competition could also come from other new immuno-oncology drugs, he said. 

The combined company will be weighed down by a heavy debt pile of more than $45 billion, restricting the use of cash for R&D, M&A and in-licensing of new assets, according to Argus. 

The Price Action

Bristol-Myers Squibb shares were down 1.1 percent at $46.34 at the time of publication Monday, while Celgene shares were down 0.61 percent at $94.84. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know

Latest Ratings for BMY

DateFirmActionFromTo
Nov 2019Initiates Coverage OnBuy
Nov 2019ReinstatesEqual-Weight
Oct 2019MaintainsNeutral

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech M&A News Downgrades Analyst Ratings Trading Ideas General Best of Benzinga

 

Related Articles (CELG + BMY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
REALDA DavidsonInitiates Coverage On22.0
RVLVDA DavidsonInitiates Coverage On19.0
SFIXDA DavidsonInitiates Coverage On27.0
CONNKeyBancDowngrades
PENNJP MorganMaintains29.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Daqo New Energy Q1 Earnings Preview

Q4 Earnings Outlook For Monro Muffler Brake